Trump Signs Executive Order to Fast-Track Psychedelic Drug Reviews, Commits $50 Million For Ibogaine Research

US President Donald Trump has signed an executive order to expedite the FDA review process for certain psychedelic drugs, with a particular focus on ibogaine, a compound eyed for treating post-traumatic stress disorder and addiction. Alongside this, the administration announced a $50 million federal investment to advance research into ibogaine’s potential, especially for veterans grappling […] The post Trump Signs Executive Order to Fast-Track Psychedelic Drug Reviews, Commits $50 Million For Ibogaine Research appeared first on the deep dive.